-
公开(公告)号：US11136352B2
公开(公告)日：2021-10-05
申请号：US17238840
申请日：2021-04-23
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Toni Weinschenk , Oliver Schoor , Claudia Trautwein , Norbert Hilf , Steffen Walter , Harpreet Singh
IPC: A61K35/17 , C07K7/06 , A61K39/00 , C07K7/08 , G01N33/574 , C07K14/74 , A61M5/00 , C12N5/0783 , A61K38/00
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号：US20210238227A1
公开(公告)日：2021-08-05
申请号：US17238806
申请日：2021-04-23
Applicant: Immatics Biotechnologies GMBH
Inventor： Toni WEINSCHENK , Oliver Schoor , Claudia Trautwein , Norbert Hilf , Steffen Walter , Harpreet Singh
IPC: C07K7/06 , A61K39/00 , C07K7/08 , A61K35/17 , G01N33/574 , C07K14/74 , A61M5/00 , C12N5/0783
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号：US11986497B2
公开(公告)日：2024-05-21
申请号：US18166936
申请日：2023-02-09
Applicant: Immatics Biotechnologies GmbH
Inventor： Toni Weinschenk , Oliver Schoor , Claudia Trautwein , Norbert Hilf , Steffen Walter , Harpreet Singh
IPC: C07K7/06 , A61K35/17 , A61K39/00 , C07K7/08 , C07K14/47 , C07K14/495 , C07K14/725 , C07K16/40 , C07K19/00 , C12N5/0783 , C12N9/02 , C12N9/10 , A61K38/00
CPC classification number: A61K35/17 , A61K39/0011 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/4748 , C07K14/495 , C07K14/7051 , C07K16/40 , C07K19/00 , C12N5/0638 , C12N9/0036 , C12N9/13 , A61K38/00 , A61K2039/5158 , A61K2039/572 , C07K2317/34 , C07K2319/00 , C12N2502/1157 , C12Y208/02011
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 11 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号：US11890334B2
公开(公告)日：2024-02-06
申请号：US17390584
申请日：2021-07-30
Applicant: Immatics Biotechnologies GmbH
Inventor： Sabrina Kuttruff-Coqui , Toni Weinschenk , Jens Fritsche , Steffen Walter , Norbert Hilf , Oliver Schoor , Colette Song , Harpreet Singh
IPC: C07K14/47 , C07K14/725 , C07K14/74 , C07K16/28 , C07K16/30 , A61P35/02 , A61P35/00 , A61K35/17 , A61K39/00 , C12N5/0783 , C07K14/705 , C07K7/06 , C07K7/08 , C12Q1/6886
CPC classification number: A61K39/0011 , A61K35/17 , C07K7/06 , C07K7/08 , C07K14/4748 , C07K14/705 , C07K14/70539 , C07K16/2833 , C12Q1/6886 , A61K2039/5158 , A61K2039/572 , A61K2039/80 , C07K2319/33 , C12Q2600/136 , C12Q2600/158 , C12Q2600/16
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号：US11759507B2
公开(公告)日：2023-09-19
申请号：US17851417
申请日：2022-06-28
Applicant: Immatics Biotechnologies GmbH
Inventor： Sabrina Kuttruff-Coqui , Toni Weinschenk , Jens Fritsche , Steffen Walter , Norbert Hilf , Oliver Schoor , Colette Song , Harpreet Singh
IPC: C07K14/47 , C07K14/725 , C07K14/74 , C07K16/28 , C07K16/30 , A61P35/02 , A61P35/00 , A61K35/17 , A61K39/00 , C12N5/0783 , C07K14/705 , C07K7/06 , C07K7/08 , C12Q1/6886
CPC classification number: A61K39/0011 , A61K35/17 , C07K7/06 , C07K7/08 , C07K14/4748 , C07K14/705 , C07K14/70539 , C07K16/2833 , C12Q1/6886 , A61K2039/5158 , A61K2039/572 , A61K2039/80 , C07K2319/33 , C12Q2600/136 , C12Q2600/158 , C12Q2600/16
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
Patent Agency Ranking
公开(公告)号：US11208434B2
公开(公告)日：2021-12-28
申请号：US17384152
申请日：2021-07-23
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Toni Weinschenk , Oliver Schoor , Claudia Trautwein , Norbert Hilf , Steffen Walter , Harpreet Singh
IPC: A61K35/17 , C07K7/06 , C12N5/0783 , C07K14/74 , A61K39/00 , A61M5/00 , G01N33/574 , C07K7/08 , A61K38/00
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号：US10906936B2
公开(公告)日：2021-02-02
申请号：US15226098
申请日：2016-08-02
Applicant: immatics biotechnologies GmbH
Inventor： Toni Weinschenk , Oliver Schoor , Claudia Trautwein , Norbert Hilf , Steffen Walter , Harpreet Singh
IPC: A61K38/00 , C07K7/06 , A61K39/00 , C07K7/08 , A61K35/17 , G01N33/574 , C07K14/74 , A61M5/00 , C12N5/0783
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号：US10434120B2
公开(公告)日：2019-10-08
申请号：US16196440
申请日：2018-11-20
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Toni Weinschenk , Oliver Schoor , Claudia Trautwein , Norbert Hilf , Steffen Walter , Harpreet Singh
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 11 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号：US20190076477A1
公开(公告)日：2019-03-14
申请号：US16196440
申请日：2018-11-20
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Toni Weinschenk , Oliver Schoor , Claudia Trautwein , Norbert Hilf , Steffen Walter , Harpreet Singh
CPC classification number: A61K35/17 , A61K38/00 , C07K7/06 , C07K7/08 , C07K14/4748 , C12N5/0638
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 11 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号：US20190076476A1
公开(公告)日：2019-03-14
申请号：US16196402
申请日：2018-11-20
Applicant: Immatics Biotechnologies GmbH
Inventor： Toni Weinschenk , Oliver Schoor , Claudia Trautwein , Norbert Hilf , Steffen Walter , Harpreet Singh
CPC classification number: A61K35/17 , A61K38/00 , A61K39/0011 , A61K2039/5158 , A61K2039/572 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/4748 , C07K14/495 , C07K14/7051 , C07K16/40 , C07K19/00 , C07K2317/34 , C07K2319/00 , C12N5/0638 , C12N9/0036 , C12N9/13 , C12N2502/1157 , C12Y208/02011
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 11 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
-
-
-
-
-
-
-
-
Search Results
33
records
(took 0.022 seconds)
